Cobimetinib - Cotellic -@-(Nov 2015)- Anti-cancer

Drug Name:
Cobimetinib - Cotellic -@-(Nov 2015)- Anti-cancer

List Of Brands:

Indication Type Description:

Drug Interaction

Indication

Adverse Reaction

Contra-Indications

Dosages/ Overdosage Etc

Patient Information

Pharmacology/ Pharmacokinetics

Pregnancy and lactation

   

Drug Interaction:

 
 Effect of Strong or Moderate CYP3A Inhibitors on Cobimetinib
 Coadministration of COTELLIC with itraconazole (a strong CYP3A4 inhibitor)
 increased cobimetinib systemic exposure by 6.7-fold. 
 
Avoid concurrent use of COTELLIC and strong or moderate CYP3A inhibitors.
 
 If concurrent short term (14 days or less) use of moderate CYP3A inhibitors
 including certain  antibiotics (e.g., erythromycin, ciprofloxacin) 
 is unavoidable for patients who are taking COTELLIC 60 mg,
 reduce  COTELLIC dose to 20 mg 
 
After discontinuation of a moderate CYP3A inhibitor  resume  COTELLIC
 at the previous dose
 
 Use an alternative to a strong or moderate CYP3A inhibitor in patients
 who are taking a reduced dose of 230 COTELLIC (40 or 20 mg daily)
 
 Effect of Strong or Moderate CYP3A Inducers on Cobimetinib
 Coadministration of COTELLIC with a strong CYP3A inducer may decrease 
 cobimetinib systemic  exposure by more than 80% and reduce its efficacy. 
 
Avoid concurrent use of COTELLIC and strong or  moderate CYP3A inducers
 including but not limited to carbamazepine, efavirenz, phenytoin, rifampin, and
 St. John’s Wort